{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreif7oegj763gj2kd2ox47otuosfs3pnfezzscbt3ogy6cvdrs3jane",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mghd7gd4xwc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreig3jat5bl2hi3aoatr6dsiul54sujqlg4cu4qdgn6j2y7a7d5tvyy"
    },
    "mimeType": "image/jpeg",
    "size": 144311
  },
  "path": "/2026/03/06/fda-uniqure-rare-disease-huntingtons/?utm_campaign=rss",
  "publishedAt": "2026-03-06T16:24:37.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Adam's Take",
    "Biotech",
    "biotechnology",
    "FDA",
    "Pharmaceuticals",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "Recent decisions at the FDA threaten to turn its disagreements with the drugmaker UniQure into another political headache for the Trump administration.",
  "title": "STAT+: The FDA, urged to avoid controversy, creates a new headache with attack against UniQure",
  "updatedAt": "2026-03-06T23:38:03.000Z"
}